Evidence map›Paper›PMID 37917179›Full record

ArticleJCI insight2023

MAFB shapes human monocyte-derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression.

Miriam Simón-Fuentes, Israel Ríos, Cristina Herrero, Fátima Lasala, Nuria Labiod, Joanna Luczkowiak, Emilia Roy-Vallejo, Sara Fernández de Córdoba-Oñate, Pablo Delgado-Wicke, Matilde Bustos and 7 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Monocyte-Derived LGMNResearch (Washington, D.C.) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Frontiers in immunology · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Miriam Simón-FuentesMyeloid Cell Laboratory, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.
Israel RíosImmunometabolism and Inflammation Unit, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Cristina HerreroMyeloid Cell Laboratory, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.
Fátima LasalaInstituto de Investigación Hospital Universitario 12 de Octubre (imas12), Universidad Complutense School of Medicine, Madrid, Spain.
Nuria LabiodInstituto de Investigación Hospital Universitario 12 de Octubre (imas12), Universidad Complutense School of Medicine, Madrid, Spain.
Joanna LuczkowiakInstituto de Investigación Hospital Universitario 12 de Octubre (imas12), Universidad Complutense School of Medicine, Madrid, Spain.
Emilia Roy-VallejoRheumatology Department, University Hospital La Princesa and Research Institute, Madrid, Spain.
Sara Fernández de Córdoba-OñateRheumatology Department, University Hospital La Princesa and Research Institute, Madrid, Spain.
Pablo Delgado-WickeMolecular Biology Unit, University Hospital La Princesa and Research Institute, Universidad Autónoma de Madrid, Madrid, Spain.
Matilde BustosInstitute of Biomedicine of Seville (IBiS), Spanish National Research Council (CSIC), University of Seville, Virgen del Rocio University Hospital (HUVR), Seville, Spain.
Elena Fernández-RuizMolecular Biology Unit, University Hospital La Princesa and Research Institute, Universidad Autónoma de Madrid, Madrid, Spain.
Maria ColmenaresMyeloid Cell Laboratory, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.
Amaya Puig-KrögerImmunometabolism and Inflammation Unit, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Rafael DelgadoInstituto de Investigación Hospital Universitario 12 de Octubre (imas12), Universidad Complutense School of Medicine, Madrid, Spain.
Miguel A VegaMyeloid Cell Laboratory, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.
Ángel L CorbíMyeloid Cell Laboratory, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.
Ángeles Domínguez-SotoMyeloid Cell Laboratory, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.
Centro de Investigaciones Biológicas Margarita Salas · ESHospital Universitario 12 De Octubre · ESHospital Universitario de La Princesa · ESHospital General Universitario Gregorio Marañón · ESInstituto de Biomedicina de Sevilla · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monocyte-derived macrophages, the major source of pathogenic macrophages in COVID-19, are oppositely instructed by macrophage CSF (M-CSF) or granulocyte macrophage CSF (GM-CSF), which promote the generation of antiinflammatory/immunosuppressive MAFB+ (M-MØ) or proinflammatory macrophages (GM-MØ), respectively. The transcriptional profile of prevailing macrophage subsets in severe COVID-19 led us to hypothesize that MAFB shapes the transcriptome of pulmonary macrophages driving severe COVID-19 pathogenesis. We have now assessed the role of MAFB in the response of monocyte-derived macrophages to SARS-CoV-2 through genetic and pharmacological approaches, and we demonstrate that MAFB regulated the expression of the genes that define pulmonary pathogenic macrophages in severe COVID-19. Indeed, SARS-CoV-2 potentiated the expression of MAFB and MAFB-regulated genes in M-MØ and GM-MØ, where MAFB upregulated the expression of profibrotic and neutrophil-attracting factors. Thus, MAFB determines the transcriptome and functions of the monocyte-derived macrophage subsets that underlie pulmonary pathogenesis in severe COVID-19 and controls the expression of potentially useful biomarkers for COVID-19 severity.

Indexed as

COVID-19SARS-CoV-2BiomarkersHumansMacrophagesMacrophages, AlveolarMafB Transcription FactorBiomarkersMAFB protein, humanMafB Transcription FactorCellular immune responseCOVID-19ImmunologyMacrophagesMolecular pathology

Identifiers

PMID37917179
PMCPMC10807725
OpenAlexW4388233765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.